Results 21 to 30 of about 151,084 (348)

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). [PDF]

, 2020
OBJECTIVES: To investigate the efficacy and safety of ixekizumab for up to 52 weeks in two phase 3 studies of patients with active radiographic axial spondyloarthritis (r-axSpA) who were biological disease-modifying antirheumatic drug (bDMARD)-naive ...
Baraliakos, X., Bertram, C.C., Bosch, F. van den, Carlier, H., COAST-V Study Grp, COAST-W Study Grp, Deodhar, A., Dougados, M., Ermann, J., Gallo, G., Gensler, L.S., Heijde, D. van der, Landewe, R., Li, X.Q., Maksymowych, W.P., Sieper, J., Tomita, T., Walsh, J.A., Wei, J.C.C., Zhao, F.Y.   +19 more
core   +3 more sources

2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

Arthritis care & research, 2019
To update evidence‐based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA).
M. Ward, A. Deodhar, L. Gensler, M. Dubreuil, David T. Y. Yu, M. Khan, N. Haroon, D. Borenstein, Runsheng Wang, A. Biehl, M. Fang, G. Louie, V. Majithia, B. Ng, Rosemary Bigham, Michael Pianin, A. A. Shah, Nancy M. Sullivan, Marat Turgunbaev, J. Oristaglio, Amy S. Turner, W. Maksymowych, L. Caplan   +22 more
semanticscholar   +1 more source

Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis?

Rheumatology, 2020
OBJECTIVE The aim of this study was to compare patients with ankylosing spondylitis with psoriasis (ASP) and without psoriasis (AS), to axial PsA (axPsA) patients. METHODS Two adult cohorts were recruited from the AS clinic: ASP and AS.
J. Feld, J. Ye, V. Chandran, R. Inman, N. Haroon, R. Cook, D. Gladman   +6 more
semanticscholar   +1 more source

Persistent clinical efficacy and safety of anti-tumour necrosis factor \textgreeka therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response [PDF]

, 2008
Background: There is insufficient evidence for the long-term efficacy and safety of anti-tumour necrosis factor therapy in patients with ankylosing spondylitis (AS).
Alten, R., Baraliakos, X., Braun, J., Burmester, G., Fritz, C., Krause, A., Listing, J., Schewe, Stefan, Schneider, M., Sieper, J., Sörensen, H., Zeidler, H.   +11 more
core   +1 more source

Insight into the Quality of Life of Patients with Ankylosing Spondylitis: Real-World Data from a US-Based Life Impact Survey

Rheumatology and Therapy, 2019
Introduction We aim to assess the real-world, US patient-reported impact of ankylosing spondylitis (AS) on quality of life (QOL) across physical, discomfort, social, and emotional domains.
James T. Rosenbaum, Lisa Pisenti, Yujin Park, Richard A. Howard   +3 more
doaj   +1 more source

Scotland Registry for Ankylosing Spondylitis (SIRAS) – Protocol [PDF]

, 2016
Funding SIRAS was funded by unrestricted grants from Pfizer and AbbVie. The project was reviewed by both companies, during the award process, for Scientific merit, to ensure that the design did not compromise patient safety, and to assess the global ...
Dean, Linda E, Gibson, Jane, Hunter, John, Jones, Elizabeth A, Jones, Gareth T, MacDonald, Alan G, Macfarlane, Gary J, Marshall, David, McEntegart, Anne, Munro, Robin, Sturrock, Roger D   +10 more
core   +1 more source

Spondylitis/Spondylodiszitis

Der Radiologe, 2006
Spondylitis is an inflammation of the vertebral body. If the infection is manifested in the vertebral motor segment it is called spondylodiscitis, which can be divided into specific and nonspecific forms. It is clinically impressive that at the beginning of the disease, the patients who are quite often immunosuppressed suffer from localized, especially
Ahlhelm, F, Kelm, J, Naumann, N, Shariat, K, Grunwald, I, Reith, W, Nabhan, A   +6 more
openaire   +4 more sources

Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice [PDF]

, 2009
The SpAs are a group of overlapping, chronic, inflammatory rheumatic diseases including AS, a chronic inflammatory disease primarily affecting the SI joints.
Elewaut, Dirk, Matucci-Cerinic, Marco
core   +1 more source

Ankylosing spondylitis: etiology, pathogenesis, and treatments

Bone Research, 2019
Ankylosing spondylitis (AS), a common type of spondyloarthropathy, is a chronic inflammatory autoimmune disease that mainly affects spine joints, causing severe, chronic pain; additionally, in more advanced cases, it can cause spine fusion.
Wei Zhu, Xuxia He, Kaiyuan Cheng, Linjie Zhang, Di Chen, Xiao Wang, G. Qiu, Xu Cao, X. Weng   +8 more
semanticscholar   +1 more source

Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis [PDF]

, 2009
OBJECTIVES:\ud To assess, quantify and summarise the cost of illness of rheumatoid arthritis (RA) and ankylosing spondylitis (AS) from the societal perspective.\ud \ud METHODS:\ud Original studies reporting costs of RA or AS were searched systematically.
Ament, A.J.H.A., Boonen, A., Franke, L.C., Laar, M.A.F.J. van de, Severens, J.L.   +4 more
core   +10 more sources